Insider Selling Dominates as Tech and Finance Executives Cash Out
LEADING SIGNAL Lisa T. Su, Chair, President & CEO of Advanced Micro Devices Inc. (AMD), sold $57.6 million in shares on June 10, 2026. This substantial divestiture by the chipmaker's top leader, amidst a week of heavy insider selling, signals a potential peak in semiconductor valuations and a shift in executive confidence regarding near-term sector performance.
TOP MOVES
- UTI — Coliseum Capital Management, LLC (insider), $124.2M. The single largest transaction of the week saw a major investor fully exiting its position in UNIVERSAL TECHNICAL INSTITUTE INC, indicating a complete loss of conviction in the educational services provider.
- SMMT — Zanganeh Mahkam (Co-Chief Executive Officer), $50.0M. This massive purchase by a co-CEO, matched by an identical buy from his counterpart Robert W. Duggan, represents an extraordinary vote of confidence in Summit Therapeutics Inc.'s pipeline and future prospects.
- BROS — Boersma Travis (Executive Chairman of Board), $92.6M. The Dutch Bros Inc. co-founder's enormous sale, coupled with a separate $60.3M divestment by DM Trust Aggregator, LLC, points to significant profit-taking and a potential top in the restaurant chain's valuation cycle.
- AMD — Su Lisa T (Chair, President & CEO), $57.6M. The CEO's large-scale sale, while potentially part of a pre-planned trading program, historically coincides with periods of heightened volatility and re-rating for the semiconductor giant.
SECTOR WATCH The data reveals concentrated selling pressure in technology-adjacent services, with 51 transactions in Services-Prepackaged Software and 25 in Electronic Computers, headlined by multi-million dollar exits from Dell Technologies Inc. (DELL) and Samsara Inc. (IOT). This pattern suggests a sector-wide reassessment of growth premiums, while the 74 transactions in Pharmaceutical Preparations, led by the colossal SMMT insider buys, indicate capital is rotating toward late-stage biotech catalysts.
TRADE TO WATCH The dual $50 million purchases by Summit Therapeutics Inc. (SMMT) Co-CEOs Zanganeh Mahkam and Robert W. Duggan on June 12, 2026, represent the week's clearest conviction signal. The thesis is that these insiders, with ultimate visibility into the company's clinical data and partnership negotiations, are betting heavily on a near-term, value-creating inflection point. This move would be confirmed by a positive clinical trial readout or a major licensing deal announcement for their lead asset. Conversely, the signal would be invalidated by a significant pipeline setback or the absence of a catalyzing corporate event within the next two quarters, rendering the capital allocation a misjudgment of risk.